Body Systems

Breast Cancer4 Results found

Studies recruiting participants:

Mindfulness-Based Treatment for Sexual Difficulties Following Breast Cancer

The purpose of this project is to compare the effects of a group mindfulness treatment versus a group sex education on sexual desire, sexual distress, and sexual pain in breast cancer survivors.  Participants will be randomly assigned to either eight weekly sessions of a group mindfulness-based t

Recruiting
Principal Investigator 
Lori Brotto
Body Locations and Systems 
Breast Cancer, Sexual Problems in Women
Area 
Vancouver
Age 
18 and above

Closed for recruitment:

Safety and Efficacy Study of Enzalutamide in Patients With Advanced, Androgen Receptor-Positive, Triple Negative Breast Cancer

The purpose of this study is to determine if enzalutamide is safe and effective in the treatment of patients with advanced breast cancer that express the androgen receptor but do not express the estrogen or progesterone receptor and are not Her2 amplified.

Closed for Recruitment
Principal Investigator 
Karen A. Gelmon
Body Locations and Systems 
Breast Cancer
Area 
Vancouver
Age 
18 and above

A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a…

This two-arm, randomized, open-label, multicenter study will evaluate the efficacy and safety of Kadcyla (trastuzumab emtansine, also known as T-DM1) in combination with Perjeta (pertuzumab) versus Herceptin (trastuzumab) in combination with Perjeta and a taxane as adjuvant therapy in patients wi

Closed for Recruitment
Principal Investigator 
Sasha Smiljanic
Body Locations and Systems 
Breast Cancer
Area 
North Vancouver
Age 
18 and above

A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a…

This two-arm, randomized, open-label, multicenter study will evaluate the effica cy and safety of Kadcyla (trastuzumab emtansine, also known as T-DM1) in combina tion with Perjeta (pertuzumab) versus Herceptin (trastuzumab) in combination wit h Perjeta and a taxane as adjuvant therapy in patients

Closed for Recruitment
Principal Investigator 
Stephen Chia
Body Locations and Systems 
Breast Cancer
Area 
Vancouver
Age 
18 and above